China Liver Cancer Clinical Registry Cohort Database
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Liver Cancer
PROCEDURE: Procedure/Surgery treatment|DRUG: Anti-Tumor Drugs
OS, Time from enrollment to first recorded occurrence of death from any cause, 10 years
RFS, Time from enrollment to the first documented occurrence of local, regional, or metastatic liver cancer or death from any cause, whichever occurs first., 10 years|Survival time after recurrence, The time from the first documented occurrence of localized, regional, or metastatic liver cancer, whichever occurs first, to death from any cause., 10 years
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.